CellSource Co., Ltd.

As of April 30, 2026, CellSource Co., Ltd. carries a market capitalization of 7.28B, placing it among publicly traded companies globally. Its enterprise value stands at 2.52B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

CellSource Co., Ltd.'s next confirmed earnings release is scheduled for December 10, 2026.

As of April 30, 2026, CellSource Co., Ltd. has 19.85M shares outstanding.

These figures are as of April 30, 2026.

As of April 30, 2026, CellSource Co., Ltd. maintains a current ratio of 10.97, meaning it holds 11.0x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended April 30, 2026.

As of the close on October 22, 2026, CellSource Co., Ltd.'s stock has declined approximately 40.71% over the past 52 weeks. The 50-day moving average sits at 329.82, while the 200-day moving average is 358.16.

As of April 30, 2026, CellSource Co., Ltd. holds 4.79B in cash and equivalents against 25.26M in total debt, resulting in a net debt position of -4.79B. Total book value stands at 5.99B, with working capital of 4.98B providing operational flexibility.

CellSource Co., Ltd.'s most recent stock split took place on October 28, 2021 with a 1:3 split ratio.